FDA & Compounding Disclaimers 1
This collaborative approach ensures that all aspects of your health are considered and that any changes in your condition can be promptly identified and addressed
liraglutide (Victoza), injectable semaglutide (Ozempic) and dulaglutide (Trulicity) have specific cardiovascular risk-reduction indications, while exenatide and oral semaglutide (Rybelsus) do not
Debido a que se administra por va intravenosa o intramuscular, el producto requiere aplicacin por personal de salud capacitado
Clinical data are compelling: In Phase 2 trials, retatrutide achieved up to 24.2% body weight reduction at 48 weeks with the highest dose, alongside HbA1c reductions of up to 2.02%results that surpass those of dual agonists and many existing therapies
GI events are dose-dependent: nausea (15-44%), vomiting (5-24%), diarrhea (8-30%), and constipation (5-24%)